These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22548227)

  • 1. [ Use of N-acetylcysteine for the prevention of contrast-induced nephropathy in rats].
    Inci MF; Salk I; Solak O; Vurdem UE; Inci R
    Actas Urol Esp; 2012 Apr; 36(4):210-5. PubMed ID: 22548227
    [No Abstract]   [Full Text] [Related]  

  • 2. [The use of acetylcysteine for preventing contrast-induced nephropathy].
    Schaad N; Barghouth G
    Rev Med Suisse; 2005 Jun; 1(25):1693-6. PubMed ID: 16117036
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravenous N-acetylcysteine in the prevention of contrast media-induced nephropathy.
    Anderson SM; Park ZH; Patel RV
    Ann Pharmacother; 2011 Jan; 45(1):101-7. PubMed ID: 21205947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase III trials.
    Stenstrom DA; Muldoon LL; Armijo-Medina H; Watnick S; Doolittle ND; Kaufman JA; Peterson DR; Bubalo J; Neuwelt EA
    J Vasc Interv Radiol; 2008 Mar; 19(3):309-18. PubMed ID: 18295688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium bicarbonate, N-acetylcysteine, and saline for the prevention of contrast-induced nephropathy.
    Bouzas-Mosquera A; Recio-Mayoral A
    Am Heart J; 2008 Apr; 155(4):e31. PubMed ID: 18371455
    [No Abstract]   [Full Text] [Related]  

  • 6. [Contrast-induced nephropathy].
    Westenfeld R; Rump LC
    Dtsch Med Wochenschr; 2013 Apr; 138(14):715-8. PubMed ID: 23533037
    [No Abstract]   [Full Text] [Related]  

  • 7. Review of contrast-induced nephropathy and current use of N-acetylcysteine (NAC).
    Anwar M; Ledger S
    CANNT J; 2005; 15(1):33-8,quiz 38-9. PubMed ID: 15909775
    [No Abstract]   [Full Text] [Related]  

  • 8. Contrast media nephropathy--how to diagnose and how to prevent?
    Solomon R
    Nephrol Dial Transplant; 2007 Jul; 22(7):1812-5. PubMed ID: 17449491
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduction of carbon tetrachloride-induced nephropathy by melatonin administration.
    Ogeturk M; Kus I; Kavakli A; Oner J; Kukner A; Sarsilmaz M
    Cell Biochem Funct; 2005; 23(2):85-92. PubMed ID: 15386528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of hydration and acetylcysteine in the prevention of contrast-induced nephropathy: a potentially catastrophic complication of the percutaneous coronary interventions.
    Iyisoy A; Celik T; Yuksel UC; Bugan B; Isik E
    Int J Cardiol; 2009 May; 134(3):431-3; author reply 434. PubMed ID: 18501445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of N-acetylcysteine on experimental chronic lead nephrotoxicity in immature female rats.
    Wang L; Wang Z; Liu J
    Hum Exp Toxicol; 2010 Jul; 29(7):581-91. PubMed ID: 20097726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acetylcysteine and contrast-induced nephropathy.
    Ritz E
    N Engl J Med; 2006 Oct; 355(14):1499; author reply 1499-500. PubMed ID: 17024738
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of contrast-induced renal dysfunction by N-acetylcysteine. Truth or myth?
    Billinger M; Hess OM; Meier B
    Eur Heart J; 2004 Feb; 25(3):188-9. PubMed ID: 14972417
    [No Abstract]   [Full Text] [Related]  

  • 14. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.
    Marenzi G; Assanelli E; Marana I; Lauri G; Campodonico J; Grazi M; De Metrio M; Galli S; Fabbiocchi F; Montorsi P; Veglia F; Bartorelli AL
    N Engl J Med; 2006 Jun; 354(26):2773-82. PubMed ID: 16807414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.
    Ferrario F; Barone MT; Landoni G; Genderini A; Heidemperger M; Trezzi M; Piccaluga E; Danna P; Scorza D
    Nephrol Dial Transplant; 2009 Oct; 24(10):3103-7. PubMed ID: 19549691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing nephropathy induced by contrast medium.
    Tepel M
    N Engl J Med; 2006 Apr; 354(17):1853-5; author reply 1853-5. PubMed ID: 16642596
    [No Abstract]   [Full Text] [Related]  

  • 17. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy.
    Trivedi H; Daram S; Szabo A; Bartorelli AL; Marenzi G
    Am J Med; 2009 Sep; 122(9):874.e9-15. PubMed ID: 19699385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease.
    Shavit L; Korenfeld R; Lifschitz M; Butnaru A; Slotki I
    J Interv Cardiol; 2009 Dec; 22(6):556-63. PubMed ID: 19732281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Has acetylcysteine use changed the incidence of contrast nephropathy in hospitalized patients? A before-after study.
    Shah SJ; Hsu CY
    Am J Med; 2004 Dec; 117(12):948-52. PubMed ID: 15629734
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).
    Ng TM; Shurmur SW; Silver M; Nissen LR; O'Leary EL; Rigmaiden RS; Cieciorka M; Porter LL; Ineck BA; Kline ME; Puumala SE
    Int J Cardiol; 2006 May; 109(3):322-8. PubMed ID: 16039733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.